BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beuckmann CT, Suzuki M, Ueno T, Nagaoka K, Arai T, Higashiyama H. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. J Pharmacol Exp Ther 2017;362:287-95. [PMID: 28559480 DOI: 10.1124/jpet.117.241422] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Ueno T, Ishida T, Aluri J, Suzuki M, Beuckmann CT, Kameyama T, Asakura S, Kusano K. Disposition and Metabolism of [ 14 C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites. Drug Metab Dispos 2020;49:31-8. [DOI: 10.1124/dmd.120.000229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Asakura S, Shiotani M, Gauvin DV, Fujiwara A, Ueno T, Bower N, Beuckmann CT, Moline M. Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant. Regul Toxicol Pharmacol 2021;127:105053. [PMID: 34619288 DOI: 10.1016/j.yrtph.2021.105053] [Reference Citation Analysis]
3 Hoyer D, Allen A, Jacobson LH. Hypnotics with novel modes of action. Br J Clin Pharmacol 2020;86:244-9. [PMID: 31756268 DOI: 10.1111/bcp.14180] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
4 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin Signaling: A Complex, Multifaceted Process. Front Cell Neurosci 2022;16:812359. [DOI: 10.3389/fncel.2022.812359] [Reference Citation Analysis]
5 Yamaguchi M, Ishikawa M, Aono Y, Saigusa T. OX2 receptors mediate the inhibitory effects of orexin-A on potassium chloride-induced increases in intracellular calcium ion levels in neurons derived from rat dorsal root ganglion in a chronic pain model. Neuropsychopharmacol Rep 2020;40:30-8. [PMID: 31845549 DOI: 10.1002/npr2.12094] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Landry I, Nakai K, Ferry J, Aluri J, Hall N, Lalovic B, Moline ML. Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults. Clin Pharmacol Drug Dev 2021;10:153-65. [PMID: 32468649 DOI: 10.1002/cpdd.817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
7 Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. JAMA Netw Open 2019;2:e1918254. [PMID: 31880796 DOI: 10.1001/jamanetworkopen.2019.18254] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 15.3] [Reference Citation Analysis]
8 Uchiyama M, Kambe D, Imadera Y, Kajiyama Y, Ogo H, Uchimura N. Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study. Psychopharmacology (Berl) 2022. [PMID: 35296912 DOI: 10.1007/s00213-022-06089-6] [Reference Citation Analysis]
9 Scott LJ. Lemborexant: First Approval. Drugs 2020;80:425-32. [PMID: 32096020 DOI: 10.1007/s40265-020-01276-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
10 Roth T, Rosenberg R, Morin CM, Yardley J, Pinner K, Perdomo C, Atkins N, Pappadopulos E, Malhotra M, Moline M. Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder. Sleep Medicine 2022. [DOI: 10.1016/j.sleep.2022.01.024] [Reference Citation Analysis]
11 Beuckmann CT, Suzuki H, Musiek ES, Ueno T, Sato T, Bando M, Osada Y, Moline M. Evaluation of SAMP8 Mice as a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer's Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant. J Alzheimers Dis 2021;81:1151-67. [PMID: 33843668 DOI: 10.3233/JAD-201054] [Reference Citation Analysis]
12 Hellmann J, Drabek M, Yin J, Gunera J, Pröll T, Kraus F, Langmead CJ, Hübner H, Weikert D, Kolb P, Rosenbaum DM, Gmeiner P. Structure-based development of a subtype-selective orexin 1 receptor antagonist. Proc Natl Acad Sci U S A 2020;117:18059-67. [PMID: 32669442 DOI: 10.1073/pnas.2002704117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
13 Sieminski M, Szypenbejl J, Partinen E. Orexins, Sleep, and Blood Pressure. Curr Hypertens Rep. 2018;20:79. [PMID: 29992504 DOI: 10.1007/s11906-018-0879-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
14 Cai Z, Liu H, Wang L, Li X, Bai L, Gan X, Li L, Han C. Molecular Evolutionary Analysis of the HCRTR Gene Family in Vertebrates. Biomed Res Int 2018;2018:8120263. [PMID: 29967787 DOI: 10.1155/2018/8120263] [Reference Citation Analysis]
15 Mano Y, Ueno T, Hotta K. Establishment of a simultaneous assay for lemborexant, a novel dual orexin receptor antagonist, and its three metabolites, and its application to a clinical protein binding study. Journal of Pharmaceutical and Biomedical Analysis 2020;187:113359. [DOI: 10.1016/j.jpba.2020.113359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
17 Beuckmann CT, Ueno T, Nakagawa M, Suzuki M, Akasofu S. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. Sleep 2019;42:zsz076. [PMID: 30923834 DOI: 10.1093/sleep/zsz076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
18 Yuan S, Yu B, Liu H. New drug approvals for 2019: Synthesis and clinical applications. European Journal of Medicinal Chemistry 2020;205:112667. [DOI: 10.1016/j.ejmech.2020.112667] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Kärppä M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, Perdomo C, Inoue Y, Ishikawa K, Kubota N. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep 2020;43:zsaa123. [PMID: 32585700 DOI: 10.1093/sleep/zsaa123] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
20 Kishi T, Nishida M, Koebis M, Taninaga T, Muramoto K, Kubota N, Moline M, Sakuma K, Okuya M, Nomura I, Iwata N. Evidence-based insomnia treatment strategy using novel orexin antagonists: A review. Neuropsychopharmacol Rep 2021. [PMID: 34553844 DOI: 10.1002/npr2.12205] [Reference Citation Analysis]
21 Zammit G, Krystal A. Evaluating lemborexant for the treatment of insomnia. Expert Opin Pharmacother 2021;22:1235-43. [PMID: 33711243 DOI: 10.1080/14656566.2021.1902987] [Reference Citation Analysis]
22 Chepke C, Jain R, Rosenberg R, Moline M, Yardley J, Pinner K, Kumar D, Perdomo C, Filippov G, Atkins N, Malhotra M. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder. Postgraduate Medicine. [DOI: 10.1080/00325481.2022.2049553] [Reference Citation Analysis]
23 Kishi T, Nomura I, Matsuda Y, Sakuma K, Okuya M, Ikuta T, Iwata N. Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis. J Psychiatr Res 2020;128:68-74. [PMID: 32531478 DOI: 10.1016/j.jpsychires.2020.05.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
24 Cheng JY, Moline M, Zammit GK, Filippov G, Bsharat M, Hall N. Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Clin Drug Investig 2021;41:449-57. [PMID: 33723806 DOI: 10.1007/s40261-021-01018-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Moline M, Zammit G, Yardley J, Pinner K, Kumar D, Perdomo C, Cheng JY. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials. Postgrad Med 2021;133:71-81. [PMID: 33119423 DOI: 10.1080/00325481.2020.1823724] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
26 Landry I, Aluri J, Hall N, Kumar D, Dayal S, Moline M, Reyderman L. Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexant. Pharmacol Res Perspect 2020;8:e00678. [PMID: 33135390 DOI: 10.1002/prp2.678] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Ueno T, Ishida T, Kusano K. Disposition and metabolism of [ 14 C]lemborexant, a novel dual orexin receptor antagonist, in rats and monkeys. Xenobiotica 2019;49:688-97. [DOI: 10.1080/00498254.2018.1482509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
28 Rosenberg R, Citrome L, Drake CL. Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. Neuropsychiatr Dis Treat 2021;17:2549-66. [PMID: 34393484 DOI: 10.2147/NDT.S297504] [Reference Citation Analysis]
29 Dayal S, Aluri J, Hall N, Filippov G, Moline M, Reyderman L, Landry I. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant. Pharmacol Res Perspect 2021;9:e00758. [PMID: 33822479 DOI: 10.1002/prp2.758] [Reference Citation Analysis]
30 Sogawa R, Emoto A, Monji A, Miyamoto Y, Yukawa M, Murakawa-Hirachi T, Tagomori Y, Kawasaki M, Kimura S, Shimanoe C. Association of orexin receptor antagonists with falls during hospitalization. J Clin Pharm Ther 2022. [PMID: 35229895 DOI: 10.1111/jcpt.13619] [Reference Citation Analysis]
31 Vermeeren A, Jongen S, Murphy P, Moline M, Filippov G, Pinner K, Perdomo C, Landry I, Majid O, Van Oers ACM, Van Leeuwen CJ, Ramaekers JG, Vuurman EFPM. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep 2019;42:zsy260. [PMID: 30597112 DOI: 10.1093/sleep/zsy260] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
32 Yardley J, Kärppä M, Inoue Y, Pinner K, Perdomo C, Ishikawa K, Filippov G, Kubota N, Moline M. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Med 2021;80:333-42. [PMID: 33636648 DOI: 10.1016/j.sleep.2021.01.048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Hamidovic A. Dual Orexin Receptor Antagonists (DORAs) as an Adjunct Treatment for Smoking Cessation. CNS Drugs 2022. [PMID: 35451800 DOI: 10.1007/s40263-022-00918-0] [Reference Citation Analysis]